Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2006 1
2007 2
2009 3
2010 3
2011 3
2014 2
2016 2
2017 2
2018 6
2019 4
2020 4
2021 5
2022 10
2023 8
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.
Sobieralski P, Bieniaszewska M, Bołkun Ł, Sacha T, Muzalewska-Wolska M, Homenda W, Bartkowiak ŁK, Smith J, Rymko M, Jachalska A, Mital AR, Prejzner W, Zaucha J. Sobieralski P, et al. Among authors: sacha t. Adv Clin Exp Med. 2024 Apr 29. doi: 10.17219/acem/182857. Online ahead of print. Adv Clin Exp Med. 2024. PMID: 38683044
High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.
Kwaśnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysogląd H, Ochrem B, Bober G, Wasilewska E, Hus I, Szarejko M, Prejzner W, Grzybowska-Izydorczyk O, Klonowska-Szymczyk A, Mędraś E, Kiełbus M, Sacha T, Giannopoulos K. Kwaśnik P, et al. Among authors: sacha t. Cells. 2024 Apr 22;13(8):723. doi: 10.3390/cells13080723. Cells. 2024. PMID: 38667336 Free PMC article.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Among authors: sacha t. Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204-y. Online ahead of print. Leukemia. 2024. PMID: 38548962
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R. Gupta V, et al. Among authors: sacha t. Leuk Lymphoma. 2024 Mar 19:1-13. doi: 10.1080/10428194.2024.2328800. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38501751
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: sacha t. Ann Hematol. 2024 Mar 4. doi: 10.1007/s00277-024-05665-4. Online ahead of print. Ann Hematol. 2024. PMID: 38438627
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian JJ, McLornan DP, Perkins A, Fox ML, McMullin MF, Mead AJ, Egyed M, Mayer J, Sacha T, Kawashima J, Huang M, Strouse B, Mesa R. Oh ST, et al. Among authors: sacha t. EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. eCollection 2024 Feb. EJHaem. 2024. PMID: 38406514 Free PMC article.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. Machova Polakova K, et al. Among authors: sacha t. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129513 Free PMC article.
63 results